Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Samonigg, H; Hossfeld, DK; Spehn, J; Fill, H; Leb, G.
Aclarubicin in advanced thyroid cancer: a phase II study.
Eur J Cancer Clin Oncol. 1988; 24(8):1271-1275
Doi: 10.1016/0277-5379(88)90214-3
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Samonigg Hellmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Twenty-four patients with metastatic thyroid cancer were treated with aclarubicin intravenously at a dose of 25-30 mg/m2 daily for 4 days and treatment was repeated every 3 weeks. None of the patients had previously received chemotherapy. Twenty-three patients received two or more treatment cycles and were evaluated for their response. One complete remission and four partial remissions were noted (objective remission rate 22%). Mean survival time was 57 weeks. Side-effects were evaluated in 24 patients with 18 patients receiving prophylactic antiemetic therapy. Nausea was observed in 18 (75%) and vomiting occurred in three patients (13%). In 15 patients (63%) there was mild myelosuppression. We conclude that aclarubicin alone represents an effective therapy in patients with metastatic thyroid cancer and that side-effects are minor.
- Find related publications in this database (using NLM MeSH Indexing)
- Aclarubicin - adverse effects
- Adult - adverse effects
- Aged - adverse effects
- Drug Evaluation - adverse effects
- Female - adverse effects
- Humans - adverse effects
- Male - adverse effects
- Middle Aged - adverse effects
- Thyroid Neoplasms - drug therapy